Table I.
Patient characteristics according to hepatocellular carcinoma etiology.
| Characteristics | NBNC (n=164) | HBV (n=144) | HCV (n=550) |
|---|---|---|---|
| Age (years)a | 70.3±7.8b,c | 60.3±10.8c | 69.4±7.6 |
| Gender (male/female) | 149/32c | 111/33 | 401/149 |
| Maximum tumor diameter (cm)a | 4.7±3.7c | 4.5±3.7c | 3.2±2.2 |
| Tumors (n)a | 1.9±2.8 | 2.0±1.6 | 2.0±2.1 |
| Disease stagea | 2.2±0.6 | 2.3±0.6c | 2.1±0.7 |
| Albumin (g/dl)a | 4.0±0.5c | 3.9±0.5c | 3.7±0.4 |
| Total bilirubin (mg/dl)a | 0.7±0.3b,c | 0.8±0.4 | 0.8±0.4 |
| AST (IU/l)a | 41±36c | 46±32c | 58±34 |
| ALT (IU/l)a | 36±36c | 39±32c | 52±37 |
| White blood cell count (/µl)a | 5,586±1,817c | 5,325±1,956c | 4,593±1,685 |
| Platelet count (x104/µl)a | 18.4±9.9c | 16.0±8.6c | 13.1±6.9 |
| Prothrombin activity (%)a | 87±13b,c | 79±13 | 82±16 |
| α-fetoprotein (ng/ml)a | 14,072±110,966c | 17,559±122,993c | 2,406±18,702 |
| DCP (mAU/ml)a | 11,827±74,826b,c | 6,726±45,768 | 1,707±8,522 |
| ICGR15 (%)a | 15±11c | 16±11 | 21±14 |
| Diabetes (+/-) | 87/94 (48%)b,c | 33/111 (23%) | 151/399 (27%) |
| Child-Pugh Classification (A/B) | 166/15b,c | 116/28 | 425/125 |
| BMI (kg/m2) | 23.9±3.8b,c | 22.7±3.8 | 22.5±3.1 |
a
Values are presented as means ± standard deviation.
b
P<0.05 vs. HBV.
c
P<0.05 vs. HCV. Disease stage represents the tumor-node-metastasis stage according to the Liver Cancer Study Group of Japan. NBNC, hepatitis B surface antigen-negative and hepatitis C virus antibody-negative patients; HBV, hepatitis B surface antigen-positive patients; HCV, hepatitis C virus antibody-positive patients; AST, aspartate aminotransferase; ALT, alanine aminotransferase; DCP, des-γ-carboxyprothrombin; ICGR15, indocyanine green retention rate at 15 min; BMI, body mass index.